The participant is using valproate for controlling his/her seizures They are eligible for the study if they had not taken valproate within 3 weeks prior to baseline visit and willing to not take it for the entire study duration Valproate is an AED that partially inhibits the TCA cycle via alpha-ketoglutarate dehydrogenase and should not be administered to subjects taking triheptanoin 